We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DRI:NYSEDarden Restaurants, Inc. Analysis

Data as of 2026-03-10 - not real-time

$203.47

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Darden Restaurants shows solid top‑line momentum with ~7% revenue growth and a respectable operating margin of roughly 10%, while its ROE exceeds 50%, indicating efficient capital use. Free cash flow remains positive and the dividend yield of just under 3% is backed by a payout ratio around 60%, suggesting sustainability. The technical picture is mixed: the 20‑day SMA sits above both the 50‑day and 200‑day averages, indicating a bullish bias, and volume is on the rise, yet the MACD histogram is negative and the RSI hovers in the low‑mid 40s, pointing to limited upside momentum in the near term. Volatility is elevated at roughly 26% over the past month, but beta is low at 0.57, implying the stock moves less than the broader market.
Recent market chatter is cautiously optimistic – analysts collectively rate the stock as a "buy" with median price targets near $225, and a bullish Substack thesis highlights the brand portfolio’s resilience. The current price of $203 offers about a 9–10% upside to the DCF‑derived fair value, though that fair value appears unusually low, flagging possible overvaluation. Overall, the dividend and cash generation are strengths, while high leverage and sector cyclicality temper enthusiasm.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish SMA alignment and increasing volume
  • Positive free cash flow supporting dividend sustainability
  • Analyst consensus buy with near‑term upside potential

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong ROE and earnings growth outlook
  • Dividend yield around 3% with comfortable payout ratio
  • Target price median around $225 suggesting ~10% upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • High debt‑to‑equity ratio raises balance‑sheet concerns
  • DCF fair value substantially below market price
  • Consumer‑cyclical exposure may limit long‑term appreciation

Key Metrics & Analysis

Financial Health

Revenue Growth7.30%
Profit Margin8.92%
P/E Ratio21.3
ROE54.10%
ROA7.20%
Debt/Equity401.27
P/B Ratio11.3
Op. Cash Flow$1.7B
Free Cash Flow$628.7M

Technical Analysis

TrendBullish
RSI43.8
Support$194.26
Resistance$220.65
MA 20$211.00
MA 50$205.69
MA 200$200.02
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair Value$32.80
Target Price$222.90
Upside/Downside9.55%
GradeOvervalued
TypeGrowth
Dividend Yield2.98%

Risk Assessment

Beta0.57
Volatility26.36%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.